Compound Profile: ABILIFY
ABILIFY 15mg is a pharmaceutical-grade aripiprazole research compound manufactured by Bristol-Myers Squibb, representing a third-generation atypical antipsychotic agent for in-vitro laboratory studies. This D2 dopamine receptor partial agonist enables researchers to investigate complex neurotransmitter modulation mechanisms within controlled experimental frameworks. Research laboratories utilise this standardised formulation to examine dopamine-serotonin pathway interactions, receptor binding kinetics, and pharmacological profiles in cellular models. The compound’s unique partial agonist properties at dopamine D2 and serotonin 5-HT1A receptors, combined with antagonist activity at 5-HT2A receptors, provide valuable insights for neuropharmacological research applications.
Laboratory Applications
Research scientists studying antipsychotic mechanisms frequently analyse ABILIFY’s distinctive receptor profile to understand functional selectivity in dopaminergic signalling. The compound enables investigation of partial agonism versus full antagonism effects on dopamine receptor systems, offering critical data for neurotransmitter research. Laboratory studies examine how aripiprazole’s unique binding characteristics influence downstream signalling cascades and receptor desensitisation patterns. Researchers at Stroid UK Shop access pharmaceutical-grade compounds for comparative studies with other antipsychotic drugs and neurobiological modulators. Advanced research protocols examine metabolic pathways, CYP enzyme interactions, and receptor occupancy profiles in cellular systems. Comparative studies with SARMs and peptides provide insights into different molecular mechanisms affecting cellular function.
Compound Specifications
| Parameter | Value |
|---|---|
| Active Compound | Aripiprazole |
| Strength | 15mg per unit |
| Manufacturer | Bristol-Myers Squibb |
| CAS Number | 129722-12-9 |
| Molecular Formula | C₂₃H₂₇Cl₂N₃O₂ |
| Molecular Weight | 448.39 g/mol |
| Storage Conditions | Room temperature, dry environment |
| Research Classification | Atypical antipsychotic |
Compliance Information
ABILIFY 15mg Bristol-Myers Squibb is supplied exclusively for in-vitro research purposes and laboratory analysis. This pharmaceutical-grade compound is not intended for human consumption, therapeutic use, or any clinical applications. Research institutions and qualified laboratories must ensure proper handling protocols and regulatory compliance when conducting studies with this antipsychotic research material. All investigations must adhere to institutional review guidelines and appropriate safety standards for pharmaceutical compound research.
